William N. William, Jr, MD

Articles by William N. William, Jr, MD

Dr William on First-Line EGFR-Mutant NSCLC in AMIGO-1

September 18th 2026

William N. William Jr, MD, discusses the design, toxicity lessons, and TP53 co-mutant signal from the phase 2 AMIGO-1 trial of amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

Latest Updated Articles

Trending on OncLive

Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma

CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma

Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC

Mosunetuzumab Plus Lenalidomide Improves PFS in R/R Follicular Lymphoma

Episode 2: Taking Stock of Systemic and Local Therapy Trends in Lung Cancer With Drs Crowley and Moghanaki